OOIR: Observatory of International Research

Papers

(The TQCC of American Journal of Hematology is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
	676
The latest insights into rare blood disorders: Diagnosis and treatment strategies	390
Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon	366
Not All Tryptase Elevations Are due to Acquired Clonal Mast Cell Disorders: When Tryptase Gene Copy Number Analysis Becomes Critical	224
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations	204
Autosomal Dominant Erythrocytosis Caused by Non‐Renal Erythropoietin ( EPO ) Due to EPO c	185
The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases	173
Primary Effusion Lymphoma Prognostic Score (PEL‐PS): A Validated International Prognostic Score in HIV‐Associated Primary Effusion Lymphoma	164
Teclistamab in patients with multiple myeloma and impaired renal function	145
Differential Prognosis and Transplant Strategies in CBF ‐ AML With	131
Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant‐Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal A	108
A First‐In‐Human Phase 1 Study of a Novel BCMA × CD3 Bispecific T Cell Engager	108
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative	105
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers	94
R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study	91
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia	90
TEG and ROTEM : Technology and Clinical Applications, 2026 Update	86
History of Thrombosis at High Altitude Associates With Increased Erythropoietin	84
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms	82
Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia	82
Introduction to American Journal of Hematology Supplement: Improving Initial Care for Acute GVHD Patients	80
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis	76
Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?	75
Are veterans at increased risk of myeloproliferative neoplasms?	74
Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients	73

Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML	72
Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transpl	72
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia	72
Clonal Hematopoiesis and Thrombosis	71
Peripheral Blood Erythrophagocytosis in Plasmodium falciparum Malaria	70
Polatuzumab Vedotin Combined With R ‐ ICE ( PolaR	69
Cytopenias revealing a case of carcinocythemia with bone marrow metastasis	65
Molecular and clinicopathologic characterization of pediatric histiocytoses	64
Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers	61
The impact of sex on platelet responses to aspirin in patients with peripheral artery disease	58
Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data	56
Diagnosis and Management of Acute Chest Syndrome in Children With Sickle Cell Disease	54
Minutes Matter: An Audit of the Timeliness of Opioid Administration for Sickle Cell Disease Pain in the Emergency Department and Association With Disposition	52
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome	52
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity	52
A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis	51
Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis: A Case Series	48
Table of Contents	48
Acute myeloid leukemia with mutated TP53: Is this newly proposed entity oversimplifying a complex group of neoplasms?	48
Triple A Plus ( AAA ⁺ ) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients	47
Harnessing the prognostic potential of PHF6 mutations in chronic myelomonocytic leukemia	47
Toward an improved understanding of hypomethylating agent and venetoclax therapies	46
Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (	45
Quick consults in hematology: Staging and treating immunoglobulin light chain (AL) amyloidosis	44
Rare circulating lymphoblasts with striking eosinophilia: A rare case of B‐lymphoblastic leukemia with PAX5::ZCCHC7	44
Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy	43
Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population‐based cohort study	43
Persistent Sweet syndrome post‐hematopoietic stem cell transplantation heralding molecular relapse of myelofibrosis	43
	43
Sodium‐glucose co‐transporter‐2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases	43
Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis‐Related Acquired Factor X Deficiency	42
A Transfusion Reaction due to Anti‐ER5 in a Hyposplenic β⁰ Thalassemia Major Patient	41
Impaired pro‐resolving mechanisms promote abnormal NETosis, fueling autoimmunity in sickle cell disease	41
Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Tera	41
Lymphocyte Kinetics and Outcomes of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma With Out of Specification Products	40
Iron Overload and Anemia in Transferrin Immune Complex Disease, an Overlooked Monoclonal Gammopathy of Clinical Significance	40
High‐Altitude Hypoxemia in Adults With Sickle Cell Disease ( SCD )	39
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003–2018)	38
A genomic‐augmented multivariate prognostic model for the survival of natural‐killer/T‐cell lymphoma patients from an international cohort	37
A randomized double‐blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficien	37
Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients	37
International Consensus Classification for myeloid neoplasms at‐a‐glance	35
Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants	35
Critical Blue‐Green Neutrophilic Inclusions in the Context of CD19 CAR ‐T Toxicity	35
Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource	35
Real‐World Outcomes of Mycosis Fungoides and Site‐Specific Nodal Involvement: A Registry‐Based Study of 25 467 Patients	34
Alloantibody to Recombinant ADAMTS13 Reduces Clinical Efficacy in Congenital TTP : An Emerging The	34
Associations Between Sex, Disease Features and Outcome in Patients With Acute Myeloid Leukemia: A Sex‐Stratified Analysis of the GIMEMA AML1310 Trial	34
Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real‐world retrospective multi‐institutional cohort	34
Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia	33

Creative and Adaptive Solutions for Early Diagnosis of Sickle Cell Disease in Sub‐Saharan Africa	33
Hydroxyurea in pregnancy: Reframing the conversation	33
Interfollicular Plasmacytosis and Hyperplastic Germinal Centers in Idiopathic Multicentric Castleman Disease, Idiopathic Plasmacytic Lymphadenopathy Subtype	33
Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries	33
Genomic Proximity Mapping for Identification of Chromosomal Aberrations in Multiple Myeloma	33
Impact of Switching From Race‐Based to Race‐Neutral Spirometry Reference Equations in Children With Sickle Cell Anemia	32
Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurre	32
Avatrombopag in immune thrombocytopenia: A real‐world study of the Spanish ITP Group (GEPTI)	31
Donor Age Matters for Haploidentical HCT Patients Even After Adjusting for HLA Factors: A Machine Learning Approach	31
Neutrophilic eccrine hidradenitis in a pediatric patient with acute myeloid leukemia	30
POEMS syndrome: Update on diagnosis, risk‐stratification, and management	30
Issue Information	30
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring	30
Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Fi	30
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy	30
Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia—aCML)	29
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors	28
A Case of Hodgkin Lymphoma in a Gaucher Disease Patient: Distinguishing Gaucher and Pseudo‐Gaucher Cells	28
Pearson syndrome	28
The Diversity of Spiculated Erythrocytes	28
LLM Abstracts Supplement	28
Elevated MCHC reveals a Southeast Asian Ovalocytosis	28
Comparison of fludarabine‐based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry‐based study	27
Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis	27
Six‐week low‐molecular‐weight heparin versus 12‐week warfarin for calf deep vein thrombosis: A randomized, prospective, open‐label study	27
Optimizing Asparaginase Treatment for Adolescent and Young Adult ( AYA ) Patients With Acute Lymphoblastic Leukemia: US	27
Distinctive Molecular Risk Factors Between MDS and MDS / AML	27
Moderate–severe beta‐thalassemia intermedia phenotype caused by sextuplicated alpha‐globin gene allele in two beta‐thalassemia carriers	27
Innovation Alone Is Not Enough: The Urgent Need for Equitable Access in Thalassemia Care	26
Correction to “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With	26
Clinical Use of Eltrombopag and Avatrombopag in Pediatric ITP in China: A Real‐World Multicenter Retrospective Cohort Study	26
The Safety and Efficacy of Commercial BCMA‐Directed CAR T‐Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma	25
Combination of Biological Aging and Genetic Susceptibility Helps Identifying At‐Risk Population of Venous Thromboembolism: A Prospective Cohort Study of 394 041 Participants	25
Different impacts of granulocyte colony‐stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type	25
Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation	25
Issue Information	25
Targeting PIEZO1 ‐ TMEM16F Coupling to Mitigate Sickle Cell Disease Complications	25
Superior GVHD ‐Free, Relapse‐Free Survival for Haploidentical Transplant With PTCy Than Matched Un	25
TACI variants as underlying condition in autoimmune neutropenia: Description of four cases	25
Myelokathexis in an 18‐year‐old male patient with severe neutropenia and lymphopenia	25
SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies	25
A CRISPR view of hematopoietic stem cells: Moving innovative bioengineering into the clinic	25
Characterization of a Newly Discovered Non‐Coding Variant in the EPO Gene Identified in Two Unrelated Italian Pedigrees With Erythrocytosis	24
Issue Information	24
Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated With Front‐Line Daratumumab Lenalidomide and Dexamethasone	24
Advancing Sickle Cell Disease Treatment in Sub‐Saharan Africa: Challenges and Opportunities for Disease Modifying Therapies	24
Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with transfusion‐dependent β‐thalassemia	24
Hematologic Landscape of Adult Patients With Diamond‐Blackfan Anemia Syndrome	24
Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study	23
Clinical Factors Associated With Catheter‐Related VTE in Patients Undergoing Hematopoietic Cell Transplantation: A Multi‐Center Study	23
Immune thrombocytopenia newly diagnosed during pregnancy: Outcome for mothers and neonates and comparison with chronic immune thrombocytopenia during pregnancy	23
Long‐term outcomes in light chain deposition disease‐analysis of a UK cohort	23
Hemolytic anemia and macrothrombocytopenia: A lipid problem?	23
Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma	22
Ex Vivo IL ‐15‐Stimulated NK Cells as Adoptive Cell Therapy in Haploidentical Transplantation for	22
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management	22
Issue Information	22
Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?	22
Thirteen‐month‐old girl with hyporegenerative macrocytic anemia due to Brown–Vialetto–Van Laere syndrome 2	22
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management	22
Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management	22
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria	22
Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events	22
The prevalence and clinical outcomes of microangiopathic hemolytic anemia in patients with biopsy‐proven renal thrombotic microangiopathy	22
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial	22
Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia	21
Myopathy related to chronic Graft‐Versus‐Host Disease: From clinic to histological & immunological characterization by imaging mass cytometry	21
Splenic Iron Overload Influence on Lumbar Spine BMD Reproducibility in β‐Thalassemia	21
Identification of a CAR‐Derived Clone by NGS‐Based MRD After Fully Human BCMA CAR T‐Cell Therapy in Multiple Myeloma	21
Immunomodulatory cytokines and clonal dynamics in low‐risk myelodysplastic syndromes patients treated with luspatercept	21
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo‐Controlled Phase 2 DELTA	21
TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis	21
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing	21
	21
Peripheral CD5+ CD10+ B‐cell proliferation with atypical morphology attributable to human herpesvirus 6 infection following umbilical cord blood transplantation	21
Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma	21
Evaluating ChatGPT as an educational resource for patients with multiple myeloma: A preliminary investigation	21
The pleiotropic effects of α‐thalassemia on HbSS and HbSC sickle cell disease: Reduced erythrocyte cation co‐transport activity, serum erythropoietin, and transfusion burden, do	20
Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis	20
The MAGIC algorithm probability (MAP)‐guided preemptive therapy of acute graft versus host disease with methylprednisolone: A randomized controlled trial	20

Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial	20
Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph‐positive leukemias	20
G‐ CSF for Mobilizing CD34 ⁺	20
Correction to “Efficacy and Safety of Early‐Start Deferiprone in Infants and Young Children With Transfusion‐Dependent Beta Thalassemia: Evidence for Iron Shuttling to Transferrin in a Randomized, Dou	20
Autoimmunity in sickle cell disease: Analysis of a large cohort of adult patients	20
DNA Methylation Episignature as a Novel Diagnostic Tool for Diamond‐Blackfan Anemia Syndrome	20
SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers	20
Generating Off‐the‐Shelf Hematopoietic Stem Cells by “Stretching” Induced Pluripotent Stem Cells	20
Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha‐thalassemia	20
Reducing transfusion utilization for children with sickle cell anemia in sub‐Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial	19
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition	19
Table of Contents	19
Venous thromboembolism after COVID‐19 vaccination in patients with thrombophilia	19
Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial	19
Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B‐Cell Non‐Hodgkin Lymphoma	19
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms	19
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by	19
Issue Information	19
Unusual complications in the management of chronic lymphocytic leukemia	19
Real World Study on the Best CPX ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation	19
2025 update on clinical trials in immune thrombocytopenia	19
Acute hemolytic anemia after hematopoietic stem cell transplantation: An unusual invader	19
‘Phenoconversion’ in adult patients with β‐thalassemia	19
RETRACTION : A predictive model of herpes zoster after allogeneic hematopoietic stem cell transplantation: VZV reactiv	18
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple	18
Hyperparathyroidism and the Hematologist	18
Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria	18
Treatment discontinuation in chronic myeloid leukemia: When, how, and why?	18
From Science to Solidarity: A Two‐Decade Collaboration in Thalassemia	18
Management of post‐autologous transplant relapse in patients with T‐cell lymphomas	18
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or ref	18
Hospital Variations in Time‐To‐Crisis‐Resolution Among Children and Adolescents With Sickle Cell Disease	18
Peripheral blood evidence of iron overload	18
	17
Response to Ribeiro Jr. et al.	17
Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort	17
JAK inhibitor treatment‐resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy?	17
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes	17
Complement biology for hematologists	17
Thrombosis risk prediction in lymphoma patients: A multi‐institutional, retrospective model development and validation study	17
Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?	17
Frequent bleeding symptoms associated with autoimmune acquired factor XIII/13 deficiency due to anti‐factor XIII A and B subunit antibodies	17
Real‐World Outcomes in NPM1 ‐Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse	16
	16
Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia	16
ALK‐positive histiocytosis of external auditory canal in a 3‐year‐old boy	16
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia	16
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA	16
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia	16
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management	16
Increased risk of venous thromboembolism in patients with gastrointestinal disorders	16
Crystal‐storing lymphocytosis	16
High incidence of malaria in patients with sickle cell disease	16
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myelo	16
Aspirin prophylaxis for hereditary and acquired thrombotic thrombocytopenic purpura?	16
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results	16
Thalassemia enters a new age … And more lies ahead	16
	16
Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment	16
Mechanistic Consequences of Piezo1 Gain‐of‐Function Variants for Decreased Red Cell Survival in Hereditary Xerocytosis	16
Real‐world implementation of the David–Carroll buprenorphine protocol for pain management in sickle cell disease	16
Space anemia unexplained: Red blood cells seem to be space‐proof	16
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria	15
DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1	15
Rate of major bleeding with ibrutinib versus bendamustine‐rituximab in chronic lymphocytic leukemia: A population‐based cohort study	15
Correction to “Risk factors for severe infection and mortality in patients with COVID ‐19 in patients with multiple myeloma and <	15
Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study	15
Recurrent Genomic Alterations in BCRi ‐Experienced CLL Patients Treated With Venetoclax: Extended	15
Correction to “Analysis of 60 Patients with Relapsed or Refractory T‐cell Acute Lymphoblastic Leukemia and T‐cell Lymphoblastic Lymphoma Treated with CD7	15
Prevalence and Risk Factors for Venous Thromboembolism in People With Inherited Bleeding Disorders: An ATHNdataset Study	15
Poor Engraftment After Posttransplant Cyclophosphamide Graft‐Versus‐Host Disease Prophylaxis in Patients With Myelofibrosis	15
The Care and Cure of the Leukemias in 2026	15
Issue Information	15
Incidence, Characteristics, and Management of Venous Thrombosis in Adult Patients With Immune Thrombocytopenia: Results From the Multicenter, Prospective Registry CARMEN‐France	15
Residual Cerebrovascular Morbidity Despite Treatment in Pediatric Sickle Cell Disease Highlights Opportunities for Earlier, Intensified Monitoring and Treatment	15
Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC‐DATAML‐MSKCC Retrospective Study	15
Basophilia Predicts Poorer Outcomes in Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis, and Myeloproliferative Neoplasm, Unclassifiable	15
Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases	15
Fulminant intravascular hemolysis resulting from Clostridium perfringens infection	15
Classic Hairy Cell Leukemia With MAP2K1 Mutation: Diagnosis and Targeted Therapy	15
The prognostic value of blood cellular indices in pulmonary embolism	15
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort	15
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications	15
Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies	14
Issue Information	14
HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy	14
Daratumumab monotherapy for relapsed POEMS syndrome	14
Therapeutic Targeting of the Activin Receptor Signaling Pathway: Proof of Concept in Myeloid Neoplasms	14
Changing hemostatic management in post‐partum hemorrhage	14
COVID‐19 mRNA vaccine‐associated cerebral venous thrombosis: Rare adverse event or coincidence?	14
Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era	14
It's More Than Complex: Further Insights Into TP53 in MPN	14
Long‐term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T‐cells	14
Normalization of Cerebral Hemodynamics After Gene Therapy in Adults With Sickle Cell Disease	14
How the United States syphilis epidemic may portend a resurgence of an unusual hematologic condition: The connection between syphilis and paroxysmal cold hemoglobinuria	14